# N-of-One

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/n-of-one

- Industry: Healthcare IT
- Headquarters: Concord, US
- Website: www.n-of-one.com
- Total disclosed funding: $7M
- Latest round: Series B (Jul 21, 2016)
- Investors on record: 2

## About

N-of-One, Inc. provides specialized clinical variant interpretation services that optimize molecular oncology labs' efficiency and reliability, enhancing personalized medicine through expert insights.Founded in 2007 and headquartered in Concord, US, N-of-One, Inc. specializes in clinical interpretation of molecular data. The company was acquired by Qiagen in January 2019, although specific terms of the deal were not disclosed. The firm has engaged in 2 deals to date, with its latest funding round being the Series B, which raised USD 7.00 mn from investors including Allumia Ventures and Excel Venture Management.N-of-One, Inc. offers QCI Precision Insights, a service that aids clinical laboratories in interpreting molecular data for hematologic malignancies. Their service features a four-tiered, evidence-based classification system that provides oncologist-vetted interpretations tailored to individual patient contexts, helping labs manage increased caseloads without expanding staff. The company primarily serves clients in North America, Europe, and Asia, focusing on enhancing patient outcomes through precision medicine.Revenue for N-of-One, Inc. is generated through a subscription-based model for clinical interpretation services, involving transactions where laboratories pay based on usage of their offerings. Their flagship services, including rapid variant interpretation and clinical decision support, are critical for laboratories striving to maintain high-quality patient care and efficiency. Pricing plans are tailored to the volume and complexity of data processed, providing clients with customized support aligned with their operations.Looking ahead, N-of-One, Inc. is poised for growth following its acquisition by Qiagen, with anticipated advancements in product offerings aimed at enhancing clinical interpretation services. The company plans to leverage its recent funding to penetrate new markets and regions, although specific targets for expansion have not been detailed. The recent funding from the Series B round, completed in January 2019, will support these initiatives and facilitate the ongoing development of their technology and services.

## Funding rounds

- Series B, Jul 21, 2016, $7M — Excel Venture Management, Allumia Ventures

## Investors

- Excel Venture Management (https://capitalatlas.ai/funds/excel-venture-management) — Series B
- Allumia Ventures (https://capitalatlas.ai/funds/allumia-ventures) — Series B